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The bispecific monoclonal antibody (biMAb) OC/TR com­
bines the anti-ovarian-cancer reactivity of the M Ovl8 monoclo­
nal antibody (MAb) with the reactivity of an anti-CD3 MAb. 
Pre-clinical studies have indicated that this biMAb is able to 
redirect the cytolytic activity of T cells towards tumour cells, 
resulting in efficient tumour-cell lysis. To assess the clinical 
potential of systemic biMAb-based cancer therapy we initiated 
a study in ovarian-cancer patients. Five patients suspected of 
ovarian cancer received l23l-OC/TR F(ab')2 i.v. Unexpectedly, 
the first patient developed side effects (grade III—IV toxicity) 
starting 30 min after infusion (p.h) of I mg of OC/TR F(ab')2. 
After approval of the Ethical Committee, the study was contin­
ued at lower dose levels (0.1 mg; 0.2 mg). However, at the
0.2-mg dose level similar side effects were observed. FACS  
analysis indicated that all peripheral T cells were coated with 
biMAb immediately following the infusion. The cytokines tu­
mour necrosis factor-a, interferon-7 and interleukin-2 showed 
maximum serum concentrations 2 h p.i. Tumour uptake ranged 
from 0.8 to 1.9% ID/kg, resulting in tumour/background ratios 
of 3 to 8. Our results suggest that at higher antibody dose levels 
OC/TR F(ab') 2 causes T-cell activation with acute release of 
cytokines. Only low doses of biMAb can be administered safely. 
Despite the interaction with T  cells, OC/TR F(ab')2 preferen­
tially localizes in tumours following i.v. administration, thus 
offering therapeutic perspectives.
© 1996 Wiley-Liss, Inc.
A decade ago, redirecting effector cells towards tumour cells 
using bispecific monoclonal antibodies (biMAbs) was pro­
posed as a new concept for cancer therapy (Perez et al, 1985). 
In this approach, biMAbs composed of an anti-tumour anti­
body on one hand and an anti-effector cell antibody on the 
other, are used to redirect the cytotoxic activity of effector cells 
towards tumour cells. T-cell target recognition and cytolytic 
activity is restricted to major-histocompatibiiity-com- 
plex(MHC)-associated epitope presentation. In vitro studies 
have indicated that MHC restriction as well as epitope 
specificity of T cells can be circumvented with biMAbs. With 
biMAbs physically linking a T cell with a tumour cell, tumour­
cell lysis could be obtained using either tumour cell lines or 
freshly isolated tumour cells (Perez et aL, 1986; Pupa et al, 
1988). In a number of pre-clinical studies, inhibition of tumour 
growth after loco-regional administration of pre-activated 
human peripheral-blood lymphocytes (PBL) retargeted with 
anti-tumour x anti-CD3 biMAbs has been demonstrated 
(Titus et al, 1987; Van Ravenswaay Claasen et al, 1994).
Clinical experience with anti-tumour X anti-CD3 biMAbs is 
limited and confined to locoregional administration of pre­
activated PBL redirected with biMAbs (Bolhuis et al> 1992; 
Kroesen et al, 1993). The first results of these studies indicated 
that locoregional administration can induce local clinical 
responses. However, with locoregional administration the 
growth of distant metastases was not controlled.
It remains to be investigated whether this approach can also 
be applied systemically. In mice with s.c. human Hodgkin 
lymphomas, i.v. administration of anti-tumour x anti-T-cell 
biMAb and pre-activated human PBL resulted in tumour-cell 
lysis and cure (Renner et al, 1994). Furthermore, in a 
syngeneic mouse lymphoma model long-term survival and cure
of the animals was demonstrated after a sole i.v. injection of 
biMAb (Brissincke/¿?/., 1991).
In vitro studies have demonstrated that, after one cytolytic 
cycle, clustered CD3/T-celI-receptor(TCR) complexes on the 
T cell can no longer transduce the lytic signal. Repeated 
addition of biMAb is required for binding newly expressed 
CD3/TCR complexes to re-engage the T cell in another lytic 
cycle (Blank-Voorthuis et al, 1993). This limitation of the 
cytolytic mechanism would indicate that administration of 
pre-coated T cells is a poor strategy, even if the retargeted T 
cells would find the target cell in vivo. Based on this, an 
approach in which the tumour cells are coated with biMAb 
seems preferable. In such an approach, it would be desirable to 
administer biMAbs systemically. The present study aimed to 
investigate localization in tumour, biodistribution and toxicity 
associated with the systemic administration of the biMAb 
OC/TR F(ab ')2 in ovarian cancer patients.
Estimates on the toxicity related to i.v. administration of 
OC/TR F(ab ')2 were based on the following observations and 
considerations. After repeated i.p. infusions of redirected 
PBL, interIeukine-2 (IL-2) and mg doses of OC/TR F(ab ')2, 
only mild toxicity was observed (Bolhuis et al, 1992). F(ab ')2 
fragments of the biMAb were chosen to exclude other cytolytic 
mechanisms (antibody-dependent cell cytotoxicity, comple­
ment activation) than redirection of T cells. A monovalent 
anti-CD3 arm lacking an Fc part excludes cross-linking of 
CD3-TCR receptor complexes, therefore no activation of 
lymphocytes was expected to occur (Segal et al, 1991). Based 
on these considerations, no or at the most mild toxicity was 
expected after a single i.v, infusion of a low protein dose of
OC/TR F(ab')z.
To visualize and quantify the biodistribution, the biMAb was 
radiolabeled. 123I was chosen as the most suitable radionuclide 
for this study because of its radiation characteristics and, 
compared with IUIn and 99niTc, its reduced tendency to 
accumulate non-specifically in liver, spleen, kidney and bone 
marrow.
A weighted antibody-dose escalation was proposed, since it 
was assumed that the biMAb uptake in tumour in terms of 
protein amount per gram of tumour would increase when a 
higher protein dose would be administered.
PATIENTS AND METHODS 
Monoclonal antibody
The biMAb OC/TR (IgGi/IgGi) was obtained after fusion 
of the MOvl8 hybridoma with spleen cells from a BALB/c 
mouse immunized with a human T-cell clone (Van Raven­
swaay Claasen et al, 1993). The MOvl8 MAb is a murine
3To whom correspondence and reprint requests should be sent, at 
Department o f Obstetrics and Gynaecology, 415 GYN, University 
Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Nether­
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antibody of the IgGi immunoglobulin sub-class that recognizes 
a 38-kDa folate-binding protein expressed on the majority of 
ovarian carcinomas as well as on adenocarcinomas of the 
Fallopian tube, endometrium and cervix (Miotti el al, 1987; 
Campbell et al, 1991), Using immunoblotting and Northern- 
blot techniques, reactivity with normal tissues was seen with 
ovarian, fallopian tube, kidney, lung, thyroid, and choroid 
plexus tissue (Weitman et al, 1992). No reactivity with bone 
marrow or peripheral-blood cells was observed (Miotti et al, 
1987). The antibody preparations were prepared and supplied 
by Centocor Europe (Leiden, The Netherlands). The product 
was subjected to a wide range of quality-control tests, including 
tests for endotoxin and pyrogen contamination. The prepara­
tion was negative in the limulus amebocyte lysate (LAL) test 
(sensitivity: 0.06 EU/mL).
Radiolabeling and quality control
F(ab ')2 fragments of OC/TR were labelled with approxi­
mately 185 MBq (5 mCi) of m l using the Iodogen method 
(Fraker and Speck, 1978). All solutions and labware used were 
sterile and pyrogen-free. Briefly, the OC/TR F(ab ')2 with 50 
mM sodium phosphate (pH 7.2) was added to an iodogen- 
coated tube (10 |xg/100 |xl). Following IG-min incubation with 
123I (370 MBq; 25 fil; Medgenix, Fleurus, Belgium), the 
reaction mixture was applied on a Sephadex G-25 column and 
eluted with PBS. The fractions containing the labelled anti­
body were pooled. Instant thin-layer chromatography was used 
to determine the presence of free 123I in the preparations. 
After labelling, the radio-immunoconjugates were subjected to 
a LAL test: these tests were negative as well.
Immunoreactivity of the preparations was assessed towards 
HeLa (human cervix-carcinoma) cells and towards Jurkat 
(CD3-positive human acute T-cell leukemia) cells, as de­
scribed (Tibben et al, 1994). Data were plotted as described by 
Lindmo et al (1984) and the immunoreactive fraction (IRF) 
was calculated from the Y-axis abscissa.
Patients
Patients enrolled in the study (n -  5) were suspected of 
having ovarian cancer and were scheduled for surgery. Patients 
had to be over the age of 18 years and had to have a life 
expectancy of at least 3 months. All patients with previous 
exposure to murine MAbs, known allergy for rodents, allergic 
diathesis, life-threatening infection, organ failure, evidence of 
recent myocardial infarction or diagnosis of a second malig­
nancy were excluded. Written informed consent was obtained 
prior to study entry. Patient characteristics are summarized in 
Table I. All studies were conducted with the approval of the 
Internal Review Board of the University Hospital Nijmegen, 
The Netherlands.
Study design
Prior to the antibody injection, patients were evaluated by 
medical history and physical examination. An electrocardio­
gram, a chest radiograph, ultrasonography of the pelvis and 
X-ray-computed tomography of the abdomen (optional) were 
obtained.
A weighted protein-dose escalation was intended, starting at 
1.0 mg. Three patients were planned to receive the same 
dosage. If no toxicity was observed, the study was to be 
continued at the next highest dose level. Endpoint of the study 
would be WHO-toxicity grade III or IV.
Patients received a single i.v. infusion of 123I-OC/TR F(ab' )2. 
The radio-immunoconjugate was diluted in 5 ml of saline and 
infused over 30 min. In order to prevent thyroid radiation, 
patients were given 100 mg potassium iodide twice a day and 
200 mg potassium perchlorate 4 times a day, orally, starting 4 
hr before the infusion and continued for 3 days. Vital signs 
were measured frequently up to 8 hr post infusion (p.i.).
Blood samples were collected just prior to antibody adminis­
tration and at various time intervals until surgery. Radioactiv­
ity in the blood as a percentage of the injected dose per gram 
(%ID/g) of blood was determined. The half-life of disappear­
ance from the blood was calculated using non-linear least- 
square regression analysis.
Planar images of chest, abdomen and pelvic region in 
anterior and in posterior views were obtained at approximately 
4, 24 and 48 hr p.i. with a preset time of 5, 10 and 15 min 
respectively. Images were obtained with a single-headed gamma 
camera (Type Orbiter, Siemens, Hoffman Estates, IL) equipped 
with a medium-energy collimator. Planar views were recorded 
using the 159-keV gamma ray peak of 123I with a symmetric 
15% window. To reduce bladder activity, patients were asked 
to void prior to imaging of the pelvic region.
The conjugate view-counting technique was used to quanti­
tate the activity uptake in some organs (Buijs et al.s 1992). 
Briefly, region-of-interest(ROI) measurements of these or­
gans were performed on anterior and posterior view images at 
all time points. After correction for background activity, the 
geometric mean of anterior and posterior images was calcu- 
ated. The absolute uptake in an organ was calculated via 
comparison with whole-body counter measurements.
Surgery was performed at approximately 72 hr p.i. in all 
patients. The tumour status was carefully mapped. Ascites or 
peritoneal washings were collected. Suspected tissues were 
either removed or biopsied. All tissues obtained at operation 
were weighed and the amount of radioactivity of 123I was 
measured using a well-type gamma counter.
FACS analysis
Two-colour fluorescence-assistant-cell-sorter(FACS) analy­
sis was performed to study the binding of OC/TR to white 
blood cells. Briefly, 100 |jl1 samples of whole blood were 
incubated with anti-IgGi-phycoerytrin (PE) (50 |xl; 10 jxg/ml; 
Southern Biotechnology Associates, Birmingham, AL) and/or 
with anti-CD3-fluorescein isothiocyanate (FITC) (15 jjul; Bec- 
ton and Dickinson, Etten-Leur, The Netherlands). Control 
samples were incubated with species and isotype-matched 
control antibodies (PE or FITC-labelled). After washing (200 
jxl HBSS, 0.5% BSA, 0.1% NaN3) red blood cells were lysed 
with FACS-lysing solution (Becton and Dickinson, Etten- 
Leur, The Netherlands). The fluorescence of the lymphocytes 
was analyzed on a Coulter Epics Elite flow cytometer (Coulter, 
Hialeah, FL).
TABLE I -  PATIENT CHARACTERISTICS AND OBSERVATIONS
Patient
number
biMAb
dose
(mg)
Age
<yr)
FIGO
stage Histology
Diff.
grade
Side
effects
Cyto­
kines RIS
01 1.0 71 IIIc serous papillary cystadenocarcinoma II 4- + +  + Müf
02 0.1 71 IIIc serous papillary adenocarcinoma III — — +
03 0.1 49 NA uterine myoma — — *
04 0.1 66 la endometrioid adenocarcinoma II + ----- +
05 0.2 56 NA serous cystadenoma + + _ j _  _ |_ -----
NA, not applicable; - ,  negative; +, positive; + + , strongly positive.
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Cytokines
Blood was collected in EDTA tubes and immediately put on 
ice. After centrifugation at 4°C, plasma was stored at -20°C 
until analysis. Plasma levels of the cytokines IL-2, tumour 
necrosis factor-a (TNF-a) and interferon-7 (IFN-7 ) were 
determined using commercial immunoradiometric assays 
(IRMA) (IL-2 and IFN; Medgenix, Fleurus, Belgium) and an 
in-house radio-immuno assay (TNF).
Humoral anti-OCITR response
Development of human anti-mouse antibodies (HAMA) 
was assessed using OC/TR F(ab ')2 in an in-house homologous 
sandwich-type IRMA. Briefly, OC/TR F(ab')2-coated polysty­
rene wells were incubated with patients’ sera. After washing, 
the bound HAMA were traced with I25I-labeled OC/TR
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RESULTS 
Radiolabeling and quality control
The labeling efficiency of the radio-iodination of the anti­
body was between 42 and 78%. After gel filtration, ITLC 
indicated that more than 95% of the 123I was protein-bound. 
The IRF was 40 to 52% for the anti-tumour arm of the biMAb 
and 76 to 84% for the anti-CD3 arm of the antibody.
Patients
Dose level 1.0 mg. Thirty minutes after the i.v. infusion of 1 
mg of 123I-OC/TR F(ab ')2 the first patient experienced the 
following symptoms: chills and headache; nausea, vomiting 
and diarrhoea; fever up to 40°C in combination with hypoten­
sion; and fatigue. Symptomatic treatment consisted of adminis­
tration of plasma substitutes, metoclopramide and paracetamol. 
At 48 hr p.i. the patient’s clinical condition was normalized.
According to the study protocol, the protein dose should be 
decreased if toxicity grade III (nausea and vomiting) or IV 
(fever in combination with hypotension) occurred. However, 
toxicity occurred at the lowest dose level. It seemed of 
scientific interest to further investigate the objectives of the 
study, and after approval of the Review Board the study was 
continued at lower dose levels, starting at 0.1 mg.
Dose level 0.1 mg. Three patients were injected with 0.1 mg 
123I-OC/TR F(ab')2. One of these patients developed fever up 
to 39°C from 8 to 10 hr p.i. No other side effects were observed.
Dose level 0.2 mg. One patient received 0.2 mg. This patient 
developed symptoms almost identical to those of the first 
patient: chills and headache; nausea and vomiting; hypoten­
sion in combination with fever up to 39.1°C. Again, plasma 
substitutes and paracetamol were given to reduce these symp­
toms. At 24 hr p.i., the patient’s clinical condition was 
normalized. Grade-IV toxicity (fever in combination with 
hypotension) had again occurred now at the 0,2-mg dose level. 
At this point the investigators decided to stop the study.
Pharmacokinetics
Blood clearance data are presented in Figure 1. The blood 
concentrations in terms of %ID/g did not appear to be related 
to the administered antibody dose. Therefore the data of all 5 
patients were pooled. Clearance of 123I from the blood could 
be described by a bi-exponential model with mean half-life 
values of 1.0 ± 0.2 hr (range: 0.7- 1.2 hr) for the distribution 
phase (T‘/2 a) and 18.1 ± 6.7 h (range: 13.0-29.6 hr) for the 
elimination phase (P/2 p), which is in the normal range for a 
F(ab ')2 fragment (Buist et al, 1993), Mean cumulative excre­
tion of the radiolabel in the urine was 63 ± 15% ID in 24 hr 
and 76 ± 16% ID in 48 hr.
Scintigraphy and dosimetric analysis of the images
On the images of 2 patients with ovarian carcinoma, the 
tumour was visualized (Fig. 2). With an antibody dose of 0.1
t ime post infusion (h)
F igure 1 -  Blood clearance of 123I-OC/TR F (ab ')? after i.v. 
adm inistration in patien ts suspected of having ovarian cancer 
(n =  5).
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Figure 2 - Anterior planar image of the pelvis at 24 hr p.i. of 
patient 04 who received 0.1 mg OC/TR F(ab')2. The image shows 
elevated tumour uptake (arrow) in the solid part of the endometri­
oid adenocarcinoma of the left ovary, whereas the cystic part 
remained photopenic (+). In the upper right part of the abdomen, 
elevated uptake in the right kidney is visualized. In the upper left 
part of the abdomen, spleen uptake is shown.
mg, tumour was imaged as early as 3 hr p.i. In the third patient, 
the ovarian-tumour deposit with a diameter of 3 cm was not 
visualized. This may have been due to activity in the urinary 
bladder. The presence of malignant tumour was surgically and 
histopathologic ally confirmed. The benign tumours of 2 pa­
tients (uterine myoma, and serous cystadenoma of the ovary) 
did not show elevated uptake.
High1231 uptake in the spleen was seen throughout the study 
in all patients. Drawing ROIs, uptake in various organs was 
calculated for all patients. The uptake in normal tissues did not 
appear to be related to the protein dose. Therefore the data of 
all 5 patients were pooled. Mean retention in organs expressed 
as %ID is presented in Table II. The uptake in the spleen was
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TABLE II -  RETENTION IN ORGANS BASED ON ROI MEASUREMENTS
Organ
Time post infusion (hr)
4 24 48
Spleen
Bone marrow 
Liver 
Kidney 
Thyroid
15.2  ±  3.8 
30 .4  ±  10.0 
8 .5  ±  5.1
1.3 ±  0.6
1.3 ±  0.2
3.9 ±  0.7 
10.1 ±  7.0 
2.5 ±  1.5 
0.7 ±  0.3 
1.0 ±  0.1
1.2 ±  0 .8
5.1 ±  3.3
1.2 ±  1.2 
0.3 ±  0 .2
0.7
!%ID; mean ± SE.
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Figure 3 -  Anterior planar image of the thorax at 3 hr p.i, of 
atient 02 who received 0.1 mg OC/TR F(ab')2- The image shows 
igh uptake in the lymphoid organs and the bone-marrow- 
containing structures.
E
calculated to be 15.2 ± 3.8% ID at 4 hr p.i. Throughout the 
study, the splenic uptake decreased to 1.2 ± 0.8% ID at 48 hr 
p.i. Particularly at the early images (1-4 hr p.i.), bone marrow 
was clearly depicted (Fig. 3). Uptake in 2 lumbar vertebrae was
1.4 ± 0.5% ID at 4 hr p.i. The bone marrow in these 2 
vertebrae constitutes 4.6% of all bone marrow (ICRP, 1975). 
Therefore, total bone-marrow uptake represented approxi­
mately 30% ID at 4 hr p.i., whereas at 48 hr p.i. total 
bone-marrow uptake was reduced to approximately 5% ID. 
The liver showed some elevated uptake. The uptake was 
calculated to be 8.5 ± 5.1% ID at 4 hr p.i. The kidneys were 
hardly visible and, in agreement therewith, the calculated 
uptake was low at 1.3 ±  0.6% ID at 4 hr p.i. Retention of the 
radiolabel in the urinary bladder was seen at all time points. 
Thyroid uptake was clearly visible at 24 hr and 48 hr p.i., 
despite the intended blockade of iodine uptake. From ROI 
measurements thyroid uptake was calculated to be approxi­
mately 1.0% ID throughout the study.
Tissue uptake
Uptake data of the 5 patients were pooled, since no 
influence of the antibody dose was observed. Three patients 
had ovarian carcinoma. In patients 01 and 02, the largest 
tumour deposits were located in the upper abdomen. The 
tumour-tissue samples weighed 0.6 and 1.0 g respectively. In 
patient 04 the tumour was confined to the left ovary. The 
tumour weighed 1.9 kg. Uptake in malignant tumour deposits 
at approximately 72 hr p.i. varied from 0.8 to 1 .9% ID/kg.
Uptake in the benign tumours of patient 03 (tumour weight: 
0.7 kg) and 05 (tumour weight: 0.2 kg) was 0.6 and 0.3% ID/kg 
respectively. Uptake in background tissue (muscle) samples 
varied from 0.1 to 0.6% ID/kg. The tumour-to-muscle ratio 
was 8, 3 and 3 for the patients with malignant tumours, 
whereas in the patients with benign tumours this ratio was 1.5 
and 1 respectively.
FACS analysis
In all 5 patients, FACS analysis revealed that, at 10 min 
before the completion of the 30-min antibody infusion, virtu­
ally all CD3+ cells (CD4+ as well as CD8+) were coated with 
OC/TR F(ab ')2 (Fig. 4). In the patients that received the 
higher protein dose levels (1.0 and 0.2 mg), the decrease of 
lymphocytes at later time points hampered accurate gating of 
large numbers of lymphocytes. Consequently, these FACS 
analyses are based on much lower lymphocyte numbers, and 
are less accurate.
Differential counting of the blood cells and the plasma 
indicated that less than 15% of the radioactivity was associated 
with the blood cells, indicating that the majority of the biMAb 
in the circulation was not cell-associated.
White-b lood-cell differentia tion
The white-blood-cell(WBC) differentiation showed relevant 
changes p.i. in 4 patients. In patient 01, this WBC counting was 
performed at only 3 time points (pre-infusion, and 24 and 48 hr 
p.i.). FACS analysis of the WBC of this patient semi- 
quantitatively showed a decrease of leucocytes at the time in 
between (pre-infusion—28 hr p.i.). In patient 03, the WBC 
differentiation did not change. In the other 3 patients, the 
absolute number of lymphocytes decreased 6 to 21 times, 
starting from half an hour p.i. (Fig. 5). At 48 hr p.i., the 
lymphocyte numbers had recovered to pre-infusion levels. The 
absolute number of granulocytes showed no consistent changes.
Cytokines
Only the patients who received the 1.0- and 0.2-mg antibody 
doses showed IL-2 concentrations above the detection limit of 
the assay shortly after the infusion. The maximum concentra­
tions were measured 2 hr p.i. At 5 and 7 hr p.i., respectively, 
the IL-2 concentrations were still elevated, while in the next 
samples obtained the following day the concentrations had 
normalized to below the detection limit. Maximum serum 
levels of TNF-a were also obtained 2 hr p.i. (Fig. 6a). The 
patients who received the higher doses (1.0 and 0.2 mg) 
demonstrated much higher TNF-a peaks than those who 
received the lower dose (0.1 mg). The TNF-a concentrations 
had normalized to pre-injection levels at approximately 24 hr 
p.i. in all patients. In the higher-dose patients (1.0 and 0.2 mg), 
serum IFN-7 levels peaked simultaneously with IL-2 and 
TNF-a (Fig. 6b). The concentrations of IL-2 and TNF-a 
correlated well with the clinical symptoms: highest levels were 
obtained in the patients who experienced the most severe side 
effects (0.2- and 1.0-mg dose level). Moreover, at the 0.1-mg 
dose, the highest TNF-a serum level was observed in the 
patient who experienced fever.
HAMA response
As early as 1 and 3 weeks p.i., respectively, elevated HAMA 
titers were detected in the serum samples of the patients who 
received the 1.0- and 0.2-mg antibody dose. One of the 3 
patients receiving the 0.1 -mg dose demonstrated apparent 
pre-existing HAMA, while no HAMA responses were ob­
served in the other 2 patients.
DISCUSSION
The present study was performed to investigate the applica­
bility of i.v. administration of the biMAb OC/TR F(ab')a* The 
toxicity and pharmacokinetics associated with the systemic 
administration of this biMAb and its potential to localize in
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F i g u r e  4 -  A typical example of FACS analysis of peripheral 
lymphocytes of patient 02 shows that immediately post infusion of 
0.1 mg OC/TR F(ab')2 all peripheral CD3+ cells are coated with 
this biMAb. However, from 5 hr p.i. onwards OC/TR cannot be 
detected on the peripheral CD3 ' cells.
ovarian tumour were studied in patients suspected of having 
ovarian carcinoma.
After i.v. infusion, tumour localization of OC/TR F(ab ')2 
could be visualized on the planar images in 2 out of 3 patients 
with ovarian carcinoma. Tumour-to-muscle ratios varied from 
3 to 8 in the 3 patients with malignant tumours, suggesting 
specific tumour retention. Buist et al (1993) reported that, 2 
days after i.v. injection of 1 mg of the parental MOvl8, F(ab ') 2 
tumour uptake was 2.4 ± 1.4% ID/kg, with mean tumour-to- 
background ratios of 4.0 ± 1.8. Tumour uptake of the OC/TR 
F(ab')2 was somewhat lower. This could be due either to the 
monovalent anti-tumour reactivity or to its interaction with T 
cells. Our findings suggest that the absolute tumour uptake
F igure 5 -  Numbers of granulocytes (O ) and lymphocytes ( • )  
before and after i.v. infusion of OC/TR F(ab')2 in patients 02, 04 
and 05.
obtained with OC/TR F(ab ')2 is the result of the ovarian- 
carcinoma-specific M Ovl8 reactivity of this biMAb. However, 
final proof on specific tumour uptake can be obtained only by 
comparing the tumour uptake of the biMAb OC/TR with that 
of a control biMAb with CD3 reactivity and an irrelevant other 
arm.
Several investigational methods provided information on 
the interaction of OC/TR F(ab')2 with CD3+ lymphocytes. 
Early planar images showed high uptake in spleen and bone 
marrow in all patients. FACS analysis revealed that during the 
i.v. infusion all peripheral CD3+ lymphocytes became coated 
with the biMAb. After completion of the infusion, the number 
of biMAb-coated lymphocytes decreased somewhat rapidly. In 
addition, the white-blood-cell differentiation showed a signifi­
cant decrease in the number of lymphocytes, starting immedi­
ately after completion of the infusion. Taken together, these 
findings suggest that the biMAb-coated lymphocytes leave the 
circulation and traffic to the lymphoid organs. Kroesen et al. 
(1994) described a similar rapid decrease of BIS-1 F(ab ') 2 
biMAb-coated lymphocytes in blood after i.v. administration 
in renal-cell-cancer patients. Their in vitro experiments indi­
cated that this could not be attributed to internalization, 
supporting the hypothesis that T cells loaded with biMAb 
leave the circulation.
In 2 patients, side effects occurred as early as 30 min after 
the i.v. infusion of 1.0 and 0.2 mg OC/TR F(ab')2. Patients 
experienced chills, headache, nausea and vomiting, diarrhoea, 
hypotension and fever until approximately 20 hr p.i. The 
observed complex of symptoms suggested the acute release of 
cytokines after the infusion of OC/TR F(ab')2. Serum levels of 
IL-2, TNF-a and IFN -7 increased immediately after the 
infusion and reached maximum concentrations at approxi­
mately 2 hr p.i. The IL-2 and TNF-a levels correlated well with 
the clinical condition of the patients: the highest levels and the 
strongest increase were observed in the patients who experi­
enced the most severe adverse reactions.
Similar symptoms were observed in renal-cell-cancer pa­
tients after i.v. administration of the biMAb BIS-1 F(ab ')2 in 
combination with s.c. injection of IL-2 (Kroesen etal ,  1994). In 
these patients, the TNF-a levels also peaked at 2 hr p.i. These 
findings suggest that the symptoms observed in the 2 studies 
are not the result of intrinsic characteristics of a particular 
MAb, but the consequence of the anti-CD3-x-anti-tumour- 
antibody construct.
A similar complex of symptoms has been reported after i.v. 
administration of the anti-CD3 MAb OKT3 in renal-trans-
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F i g u r e  6 - ( a )  TNF-a serum levels before and after i.v. infusion 
of the biMAb OC/TR F(ab')2 in patients suspected of having 
ovarian carcinoma, (b) IL-z, IFN-7 and TNF-a serum levels before 
and after i.v. infusion of 0.2 mg of the biMAb OC/TR F(abf)2 
(patient 05).
Diant patients (Abramowicz et a l} 1989). The serum cytokine 
evels showed a pattern of prompt increase of both TNF-a and 
IFN-7 . It is thought that the acute symptoms are caused by 
cytokine release resulting from T-cell activation by the OKT3 
MAb. In vitro studies indicate that intracellular clustering of 
the CD3/TCR complex is a prerequisite for effective T-cell 
activation with anti-CD3 MAbs (Segal et al, 1991). However, 
this clustering can occur only when the biMAb is immobilized 
(e.g., via an intact Fc part or via an antibody-antigen interac­
tion) (Segal et al, 1991), The anti-tumour MAb MOvl8 is 
reactive with an epitope with very restricted expression on 
normal tissue (Miotti et al, 1987; Weitman et al, 1992). It was
therefore assumed that F(ab ')2 fragments of the biMAb 
OC/TR cannot induce such clustering except in the presence 
of tumour cells. Theoretically, any cells expressing the MOV18 
antigen could serve as a template for CD 3/TCR-comp I ex 
clustering- Assuming that a limited number of T cells would 
have to be activated to produce cytokines in concentrations 
able to cause the observed side effects, this could have 
happened in any tissue of the body expressing the MOvl8 
epitope.
It has been suggested that the presence of trace quantities of 
intact anti-CD3 in the biMAb preparations could induce T-cell 
activation (Weiner et ctL, 1994). In our study this appeared 
highly unlikely, since high-performance liquid-chromatogra- 
phy analysis of the OC/TR F(ab ')2 preparation confirmed the 
absence of any intact IgG molecules.
Kroesen et al. (1994) proposed that the increase in serum 
cytokine levels may be the result of local activation of T cells at 
the site of the tumour after cross-linking of the biMAb with 
tumour antigens. However, we also observed the syndrome in a 
patient without any known malignant tumour lesion (patient 
number 05). In addition, T-cell activation occurred very early 
after injection, whereas localization of MAbs in tumours 
occurs somewhat later.
In conclusion, the concept of redirecting effector cells of the 
immune system towards tumour cells using bispecific antibod­
ies is an attractive therapy concept for cancer patients. In 
potential, the biMAb OC/TR offers therapeutic perspectives, 
since the i,p. administration of this biMAb, in combination 
with pre-activated PBL, resulted in clinical responses. Toxicity 
of i.v. administered biMAb seems to be dose-dependent, with 
evident clinical symptoms at 0.2 and 1.0 mg (2 patients) and 
only sub-clinical changes in leucocyte differentiation counts at 
the 0,1-mg dose (3 patients). Based on our observations, the 
maximal tolerated dose after a 30-min i.v. infusion is 0.1 mg, 
Repeated injections with 0.1 mg or even lower doses of biMAb 
may circumvent the toxicity while still allowing sufficient 
tumour uptake. It is possible that i.p. administration may serve 
as a continuous systemic infusion of low doses of biMAb. 
Further studies are required to better understand the mecha­
nisms involved in T-cell activation and the effects at the site of 
the tumour after systemic administration of the bispecific 
antibody OC/TR.
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